Inference on treatment effects for targeted clinical trials under enrichment design

Pharmaceutical Statistics

Volumn 8, Issue 4, 2009, Pages 356-370

  Liu, Jen Pei ^a,b   Lin Jr , Rung ^a   Chow, Shein Chung ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bootstrap method; EM algorithm; Positive predictive value; Targeted clinical trials

Indexed keywords

ACCURACY; ALGORITHM; ARTICLE; BOOTSTRAPPING; CONFIDENCE INTERVAL; DRUG TARGETING; HUMAN; PROBABILITY; SIMULATION; STATISTICAL ANALYSIS; THERAPY EFFECT;

ALGORITHMS; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; CONFIDENCE INTERVALS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 73949142341     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.364     Document Type: Article

References (19)

1. US FDA. Guidance on pharmacogenetic tests and genetic tests for heritable marker. The US Food and Drug Administration: Rockville, MD, 2007.
2. US FDA. Draft guidance on in vitro diagnostic multivariate index assays. The US Food and Drug Administration: Rockville, MD, 2007.
3. Chow SC, Liu JP. Design and analysis of clinical trials (2nd edn). Wiley : New York, 2004.
4. US FDA. Annotated redlined draft package insert for Herceptins. The US Food and Drug Administration: Rockville, MD, 2006.
5. US FDA. Decision Summary P980018. The US Food and Drug Administration: Rockville, MD, 1998.
6. Liu JP, Chow SC. Issues on the diagnostic multivariate index assay and targeted clinical trials. Journal of Biopharmaceutical Statistics 2008; 18:167-182.
7. Dempster AP, Laird NM, Rubin DB. Maximum likelihood estimation from incomplete data via the EM algorithm (with discussion). Journal of Royal Statistical Society, Series B 1977; 39:1-38.
8. McLachlan GJ, Krishnan T. The EM algorithm and extensions. Wiley: New York, 1997.
9. Efron B, Tibshirani RJ. An introduction to the bootstrap, Chapman and Hall: New York, 1993.
10. US FDA. The draft concept paper on drug-diagnostic co-development. The US Food and Drug Administration: Rockville, MD, 2005.
11. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions (3rd edn). Wiley: New York, 2003.
12. McLachlan GJ, Peel D. Finite mixture models. Wiley: New York, 2000.
13. Nityasuddhi D, Böhning D. Asymptotic properties of the EM algorithm estimate for normal mixture models with component specific variances. Computational Statistics and Data Analysis 2003; 41:591-601.
14. Basford KE, Greenway DR, McLachlan GJ, Peel D. Standard errors of fitted component means of normal mixtures, Computational Statistics 1997; 12(1):1-17.
15. Namboodiri KK, Kaplan BB, Heuch I et al. The Collaborative Lipid Research Clinical Family Study: biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins. Genetic Epidemiology 1985; 2:227-254.
16. Miller NE, Miller GJ. High-density lipoprotein and atherosclerosis. Lancet 1975; 1:1033.
17. Nissen SE, Tardif JC, Nicholls SJ for the ILLUSTRATE Investigators. Effect of torcetrapib on the progress of coronary atherosclerosis. New England Journal of Medicine 2007; 356:1304-1316.
18. Kathiresan S, Melander O, Anevski D et al. Polymorphism associated with cholesterol and risk of cardiovascular events. New England Journal of Medicine 2008; 358:1240-1249.
19. Carlin BP, Louis TA. Bayes and empirical bayes for data analysis. Chapman and Hall: New York, 1998.